Will This New Obesity Drug Top Expectations or Disappoint?

The Motley Fool's health-care show Market Checkup focuses this week on obesity, one of America's largest health-care concerns. Recently classified as a disease, obesity leads to serious health problems including diabetes, heart disease, and stroke. Currently 35% of adults in the U.S. are classified as obese, but more troubling, one out of three children is as well. All told, obesity adds $190 billion in medical costs to the system, but efforts to tackle this growing problem are increasing.

In this video, health-care analysts David Williamson and Max Macaluso discuss Arena Pharmaceuticals, maker of Belviq, the first new obesity drug approved in more than a decade. Arena just launched Belviq after a long period of DEA scheduling, but can it avoid the pitfalls and struggles that have weighed heavily on its chief competitor? Watch and find out.

Rising health-care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health-care system -- and how to potentially profit from this trend -- click here for free, immediate access.

Follow David on Twitter: @MotleyDavid.

Read/Post Comments (3) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 29, 2013, at 2:28 PM, adumfraudstain wrote:

    Belviq 1st full week's IMS channel check scripts at 1829 only running 17.25X over Qsymia's reported 1st full week's channel check scripts (106).

    Wonder who the fool was that Tweeted 6,000 scripts tba Friday for Belviq Thursday evening? Lol!

  • Report this Comment On June 29, 2013, at 8:25 PM, wayouy wrote:

    Some Boards say you tweeted it. #'s are ok for 2nd week. Market says 9% hair cut.

  • Report this Comment On July 01, 2013, at 3:05 AM, Foreeverlong wrote:

    Oh my god! David and Max, what are you guys doing? Worthless use of time! Don't bother to watch this. I subscribe to this organization, and I can't believe this drivel. If you guys want to do this stuff, you need to study up on what you are talking about, and offer something of value. Absolutely worthless!

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2516710, ~/Articles/ArticleHandler.aspx, 9/30/2016 11:18:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,277.34 133.89 0.74%
S&P 500 2,166.40 15.27 0.71%
NASD 5,301.70 32.54 0.62%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 10:56 AM
ARNA $1.74 Down -0.01 -0.46%
Arena Pharmaceutic… CAPS Rating: ***
VVUS $1.14 Up +0.01 +0.44%
VIVUS CAPS Rating: **